|Bid||227.68 x 1000|
|Ask||233.93 x 1100|
|Day's Range||223.91 - 228.04|
|52 Week Range||177.63 - 276.43|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||26.60|
|Earnings Date||Feb 21, 2024 - Feb 26, 2024|
|Forward Dividend & Yield||1.36 (0.60%)|
|Ex-Dividend Date||Nov 14, 2023|
|1y Target Est||240.75|
Subscribe to Yahoo Finance Plus to view Fair Value for TFX
Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular AccessWAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry that is intended to examine and collect data on outcomes of contemporary on-label use of the MANTA™ Vascular Closure Device (VCD) in standard